Latest News Feed
- October 22 investor event will explore eXoZymes' commercialization, manufacturing economics, path to market launch, growth strategy, and milestones ahead.
Program expected to commence in Q4 2026 and establish a roadmap for larger-scale production in 2027
Management to host Q2 2026 update at 5PM ET / 2PM PT, today.
Optimized process delivered a 10-fold improvement in productivity, significantly improving the estimated economics of future commercial-scale manufacturing.
Estimated manufacturing cost equivalent has fallen more than 100x from the first version of the NCT process to the current optimized process, based on internal process-cost assessments.
The new process produced approximately 67% more NCT per liter than the previously announced 100-liter pilot run.
Reaction time was reduced by over 80%, allowing substantially more product to be produced in less time.
The improvements support a more scalable and efficient manufacturing process as eXoZymes prepares for technology transfer to future commercial partners.
Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar on Thursday, August 20, 2026, at 5:00 PM Eastern Time to discuss its results for the second quarter 2026. A press release detailing these results will be issued prior to the call.
Company to collaborate with Lawrence Berkeley National Laboratory on AI-enabled digital twins designed to accelerate optimization of enzyme-driven manufacturing processes.
The 9-month project awarded approximately $747,000 in total funding, including $147,000 awarded to eXoZymes
Expands eXoZymes' AI strategy beyond enzyme engineering into AI-guided manufacturing, leveraging digital twins to predict, optimize and accelerate development of cell-free bioprocesses.
Provides access to the DOE Genesis Mission Platform, including advanced AI models, AI agents and high-performance computing infrastructure to accelerate future platform development.
Award allows eXoZymes to expand its portfolio of proprietary new-to-nature molecules and potential future pharmaceutical assets and validates the Company's ability to make rare cannabinoids and new cannabinoid-like molecules.
NIH-backed work on the two-year grant is expected to begin on July 1, 2026, and represents the second biosolution in eXoZymes' pipeline after NCT advancing towards partnership and commercialization.
Total non-dilutive funding awarded to eXoZymes is now almost $20 million, validating the scalable nature of the Company's platform
Management to Host Conference Call Today at 5:30 PM Eastern
N-trans-caffeoyltyramine (NCT) is an interesting naturally occurring compound that has attracted scientific attention in exploratory studies related to lipid metabolism and energy utilization pathways.
The production was executed by an external partner under pilot-scale conditions using standardized protocols.
The pilot run achieved approximately 99% reaction conversion, 90% isolated yield, and 535 grams of NCT at 99.6% pharma-grade purity.
Reaction performance was observed to improve at increased operating scale.
High-purity NCT now available for formulation development with commercial partners.
Management to host Q3 2025 update at 5:00PM Eastern Time, today.
Management to host earnings call at 5:00PM Eastern Time, today.
Using eXoZymes' AI-driven exozymes platform, NCTx has demonstrated lab scale validation with 4 grams of NCT produced at a 96% yield and with a purity higher than 99%.
NCT project went from concept to gram scale production in 5 months and at a fraction of normal SynBio R&D cost.
N-trans-caffeoyltyramine (NCT) is a natural product compound attracting considerable interest from researchers and drug developers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial activity.
Early access partners under material transfer agreement can sample the product and eXoZymes and NCTx is actively looking to increase the number of partners.
N-trans-caffeoyltyramine (NCT) is a natural bioactive compound attracting considerable interest from researchers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial activity.
Using eXoZymes' AI-driven platform, a new and proprietary approach to biomanufacturing of NCT - with all the scale-up advantages of an exozyme biosolution - has been developed: Progressing from concept to lab scale validation with gram-scale production in only 5 months and at a fraction of normal SynBio R&D cost.
NCTx was created as a spin-out company to commercialize the NCT technology and is now able to provide early access partners, under material transfer agreement with product samples. NCTx and eXoZymes are actively looking to increase the number of partners.
Management to host earnings call at 5:00PM Eastern Time, today.
N-trans-caffeoyltyramine (NCT) is a natural product compound attracting considerable interest from researchers and drug developers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial activity.
eXoZymes used its AI-driven development platform to progress from idea to purpose-built subsidiary in less than 3 months and at a fraction of normal SynBio R&D cost.
NCTx is scaling up an exozyme biosolution to overcome a longstanding bottleneck in sourcing the NCT compound from nature, where it occurs only in trace amounts.
Interesting pre-clinical data point towards Non-Alcoholic Fatty Liver Disease (NAFLD) that affects more than 30% of the global population.
Only NCTx can make both the natural product NCT, and a range of very interesting new-to-nature analog versions, expanding the pharma potential.
NCT is the first of more "powered by eXoZymes" natural product nutraceuticals, that also have the potential to become pharmaceuticals.